Episodes
Friday Jul 28, 2023
Friday Jul 28, 2023
The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines were recently updated with a focus on kidney health in patients with diabetes. The updated guidelines include recommendations on screening, prevention, and treatment of chronic kidney disease (CKD), including the use of SGLT2 inhibitors, finerenone, and ACE inhibitors or ARBs. The written commentary posted on the iForumRx website provides a succinct summary of the Top Ten Things Every Clinician Should Know.
Guest Authors: Kara Olstad, PharmD; Gurminder Sanghera, BSc, PharmD; and Darren Grabe, PharmD
Music by Good Talk
Friday Feb 03, 2023
Friday Feb 03, 2023
Hyperkalemia is a common electrolyte disorder in patients with CKD that can be exacerbated by renin-angiotensin-aldosterone system (RAAS) inhibitors. While hyperkalemia poses potential risks to patients with CKD, the potentially negative impact of discontinuing RAAS inhibitor therapy on long-term renal and cardiovascular outcomes in CKD patients is unclear.
Guest Author: Michelle A. Fravel, PharmD, BCPS
Music by Good Talk
Thursday Apr 21, 2022
Thursday Apr 21, 2022
Published in Diabetes Care every January, the Standards of Medical Care in Diabetes by the American Diabetes Association (ADA) provides recommendations for the care of patients with diabetes. And every year clinicians eagerly read, discuss, and apply them in their practices. In this episode, we discuss some of the highlights.
Guest Author: Jennifer N. Clements, PharmD, BCPS, BCACP, CDCES, BC-ADM
Special Guest: Joshua Neumiller, PharmD, CDCES
Music by Good Talk
Friday Mar 25, 2022
Thiazides in Chronic Kidney Disease: New Evidence Challenging Old Dogma
Friday Mar 25, 2022
Friday Mar 25, 2022
Thiazide diuretics have been in clinical use for more than 60 years. Small studies published in the 1950s/60s reported that chlorothiazide had less diuretic and antihypertensive effect in patients with lower glomerular filtration rates which led to the belief that thiazides are ineffective in advanced CKD. The Chlorthalidone in Chronic Kidney Disease (CLICK) Trial challenges this dogma.
Guest Authors: Michael Ernst, PharmD, BCGP and Michelle A. Fravel, PharmD, BCPS
Music by Good Talk
Tuesday Mar 01, 2022
Extra Protection? Finerenone Use in Patients with Type 2 DM and CKD
Tuesday Mar 01, 2022
Tuesday Mar 01, 2022
Despite prevention efforts, about 1 in 3 patients diagnosed with diabetes have comorbid CKD. Half of these individuals have moderate to severe disease. Unlike patients with type 1 diabetes where it develops after many years after the diagnosis, CKD is commonly present at diagnosis in patients with type 2 diabetes. While many interventions are available to prevent the progression of CKD, more are needed.
Guest Authors: Katherine Montag Schafer, PharmD, BCACP, CDCES and Kyle Hunt, MD
Music by Good Talk
Thursday Jun 24, 2021
Raised From The Grave: A Second Life for Sotagliflozin?
Thursday Jun 24, 2021
Thursday Jun 24, 2021
The prevalence of heart failure in patients with diabetes is four times higher than in the general population. Likewise, chronic kidney disease (CKD) and diabetes are common morbidities. As new drug classes emerge in the management of diabetes and heart failure and CKD, it is important to thoroughly evaluate available literature and identify opportunities to reduce complications and costs. Sotagliflozin is a first-in-class dual SGLT-1 and 2 inhibitor approved in Europe. Does it improve outcomes in patients with heart failure or CKD?
Guest Authors: Maren Richards Brinton, PharmD and Jonathan C. Hughes, PharmD, BCPS, BCACP
Music by Good Talk
Friday Jan 29, 2021
DECLARE-ing Another Victory for Dapagliflozin
Friday Jan 29, 2021
Friday Jan 29, 2021
Until now, only two classes of medications have been definitively shown to delay the decline in renal function in patients with CKD: angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs). The sodium glucose co-transporter 2 inhibitors are increasingly prescribed to a wider and wider population of patients. And the latest data suggest they may have an important role in the treatment of chronic kidney disease (CKD) in patients with ... or without ... diabetes.
Guest Authors: Stefanie C. Nigro, PharmD, BCACP and Jennifer N. Clements, PharmD, BCPS, BCACP, CDCES, BC-ADM
Music by Good Talk
Friday Oct 13, 2017
Painting a New CANVAS for SGLT-2 Inhibitors?
Friday Oct 13, 2017
Friday Oct 13, 2017
While good glycemic control has been shown to prevent microvascular complications (e.g. retinopathy, nephropathy, neuropathy), only a few anti-diabetic agents have been shown to reduce macrovascular complications (e.g. cardiovascular events. Empagliflozin, a sodium glucose transporter-2 (SGLT2) inhibitor, not only reduced the risk of CV events but also all-cause mortality in the EMPA-REG OUTCOME study. Based on this data, the SGLT2 inhibitors were given favorable second-line treatment status in the most recent AACE/ACE clinical practice guidelines. But do all SGLT2 inhibitors confer the same benefits… and risks? The Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes (CANVAS) trial assessed the cardiovascular and renal benefits from long-term canagliflozin use. The results are both reassuring and unexpected.
Guest Author: Sean Lasota, Pharm.D.
Music by Good Talk
Friday Nov 11, 2016
Friday Nov 11, 2016
Approximately one in three patients with diabetes in the United States have chronic kidney disease (CKD). The Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME) trial, published in 2015, demonstrated a reduction in cardiovascular and all-cause mortality in patients treated with empagliflozin. More recent data from the EMPA-REG OUTCOME trial suggests that empagliflozin may also confer significant renal protection.